MDSM News Medistem to Hold Investor Conference Call to Discuss First Clinic Licensed to Deliver Company's Proprietary Stem Cell Treatments; CEO to Outline Progress to License Stem Cell Technology to Additional Clinics and Laboratories Worldwide
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Aug. 11, 2006--Medistem Laboratories, Inc. (OTCBB:MDSM) (FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, will hold an investor conference call on Monday, August 14, 2006, at Noon Eastern to review recent business milestones and events, including the licensing of the Company's first affiliated clinic and stem cell bank.
During the scheduled conference call, Neil Riordan, Ph. D., Chairman and Chief Executive Officer of Medistem, will update investors on such news as the recently-announced licensing of a stem cell bank and clinic, operated by the Company's Costa Rican affiliate, the Institute for Cellular Medicine (ICM). The Costa Rican Ministry of Health recently granted ICM's facility a license to conduct operations. It is one of the first adult stem cell banks and treatment facilities in Latin America.
"The opening of the Costa Rican clinic is an important step toward Medistem's strategic corporate vision to develop medically important therapies and open clinics around the world," said Chris McGuinn, Medistem's Chief Operating Officer. "The ICM stem cell bank and treatment clinic are now operating and physicians there are delivering stem cell treatments based on Medistem's adult stem cell technology. It's a very exciting event for Medistem."
Under the licensing agreement with ICM, which is controlled by Medistem's Chief Executive Officer, Medistem granted a license to ICM to use certain of its intellectual property and agreed to fund all necessary operating expenses in exchange for certain revenues and gross profits involving both adult stem cells and non-stem cell based activities.
Medistem is currently in negotiations to license its technology to additional laboratories and clinics in locations around the world, including Germany, Switzerland, Bulgaria, Singapore, and Mexico. If licenses are granted, these licenses would grant the international licensees the ability to further develop medically needed therapies based on Medistem's patent-pending, proprietary adult stem cell technologies, and enable fee-for-service patient treatments.
Additionally, Mr. Riordan will update investors on the Company's ongoing initiative to continue strengthening its intellectual property portfolio with new proprietary technology. These include Medistem's recent filing for a patent that might lead to treatments for erectile dysfunction (ED) through the use of stem cell therapies. The market for ED drugs and other treatments now totals approximately $3 billion per year, according to Drug Store News.
Following the presentation, management will take questions from investors. To participate in the 12:00pm EDT August 14th call, callers from within the United States may dial (888) 428-4479. When prompted, please tell the operator that you would like to connect to the Medistem conference call. This call is free of charge to all interested investors. International callers can dial (612) 234-9960. A simultaneous audio webcast of the conference call will be available at http://www.trilogy-capital.com/tcp/medistem/conference.html and will be subsequently archived for future reference at http://www.trilogy-capital.com/tcp/medistem/.
Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The Company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the Company believes to be non-controversial sources of stem cells. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. For more information on Medistem please visit http://www.trilogy-capital.com/tcp/medistem/. Medistem common stock is traded on the Frankfurt, Germany stock exchange under the symbol S2U.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.
